APA (7th ed.) Citation

JM, T., JM, M., G, G., SP, F., & RC, D. (2020). Glycoengineering of AAV-delivered monoclonal antibodies yields increased ADCC activity. Molecular therapy. Methods & clinical development, 20, 204. https://doi.org/10.1016/j.omtm.2020.11.001

Chicago Style (17th ed.) Citation

JM, Termini, Martinez-Navio JM, Gao G, Fuchs SP, and Desrosiers RC. "Glycoengineering of AAV-delivered Monoclonal Antibodies Yields Increased ADCC Activity." Molecular Therapy. Methods & Clinical Development 20 (2020): 204. https://doi.org/10.1016/j.omtm.2020.11.001.

MLA (9th ed.) Citation

JM, Termini, et al. "Glycoengineering of AAV-delivered Monoclonal Antibodies Yields Increased ADCC Activity." Molecular Therapy. Methods & Clinical Development, vol. 20, 2020, p. 204, https://doi.org/10.1016/j.omtm.2020.11.001.